利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.028 秒)

    DELIVERY OF ACTIVE AGENTS
    3.
    发明申请
    DELIVERY OF ACTIVE AGENTS 审中-公开
    交付活性剂

    公开(公告)号：WO2009055742A2

    公开(公告)日：2009-04-30

    申请号：PCT/US2008081221

    申请日：2008-10-24

    申请人： MANNKIND CORP ,  BAUGHMAN ROBERT A ,  RICHARDSON PETER ,  COSTELLO DONALD ,  LEONE-BAY ANDREA

    发明人： BAUGHMAN ROBERT A ,  RICHARDSON PETER ,  COSTELLO DONALD ,  LEONE-BAY ANDREA

    CPC分类号： A61K9/0075 ,  A61K9/1617 ,  A61K9/1688 ,  A61K31/495 ,  A61K38/26

    摘要： A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.

    摘要翻译： 本文公开了将生理活性剂引入哺乳动物的循环系统中的方法。 该方法利用快速的药物递送系统，其防止正在施用给需要治疗的患者的活性剂的失活或降解。 特别地，药物递送系统被设计用于肺部药物递送，例如通过吸入，用于以治疗有效的方式将活性剂（例如蛋白质和肽）递送到肺循环中，以避免在外周和血管组织中的活性剂的降解， 到达目标网站。

    METHODS TO BYPASS CD+4 CELLS IN THE INDUCTION OF AN IMMUNE RESPONSE
    6.
    发明申请
    METHODS TO BYPASS CD+4 CELLS IN THE INDUCTION OF AN IMMUNE RESPONSE 审中-公开
    CD + 4细胞在诱导免疫反应中的作用方法

    公开(公告)号：WO2006071990A9

    公开(公告)日：2006-12-07

    申请号：PCT/US2005047442

    申请日：2005-12-29

    申请人： MANNKIND CORP ,  DIAMOND DAVID C ,  BOT ADRIAN ION

    发明人： DIAMOND DAVID C ,  BOT ADRIAN ION

    CPC分类号： A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55561 ,  A61K2039/57 ,  C12N2730/10134 ,  C12N2740/16234

    摘要： Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.

    摘要翻译： 本文公开的本发明的实施方案涉及用于在产生抗体和MHC I类限制性免疫应答，控制应答性质和程度以及促进病毒发病机制中的有效免疫干预时绕过CD4 +细胞的参与的方法和组合物。 更具体地说，实施方案涉及用于免疫接种的免疫原性组合物，特别是治疗性疫苗接种，针对影响免疫系统功能的HIV和其他微生物病原体，其性质以及它们有效使用的施用顺序，时机和途径。

    TUMOR-ASSOCIATED ANTIGEN PROFILES IN CANCER DIAGNOSTICS AND IMMUNOTHERAPY
    7.
    发明申请
    TUMOR-ASSOCIATED ANTIGEN PROFILES IN CANCER DIAGNOSTICS AND IMMUNOTHERAPY 审中-公开
    肿瘤相关抗原在癌症诊断和免疫学中的分布

    公开(公告)号：WO2006002114A3

    公开(公告)日：2006-10-05

    申请号：PCT/US2005021836

    申请日：2005-06-17

    申请人： MANNKIND CORP ,  CHIANG CHIH-SHENG ,  SIMARD JOHN J L

    发明人： CHIANG CHIH-SHENG ,  SIMARD JOHN J L

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57484

    摘要： Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for confirming diagnosis of a particular type of cancer. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs to optimize the match between a patient's cancer condition and available immunotherapies.

    摘要翻译： 本文公开了将癌症状况与适当的免疫治疗剂和/或方案进行匹配的方法。 还公开了用于确认特定类型的癌症的诊断的方法。 本文公开的本发明的实施方案涉及使用TuAAs的有效组合来优化患者的癌症状况与可用的免疫疗法之间的匹配。

    DRY POWDER DRUG DELIVERY SYSTEMS AND METHODS
    9.
    发明申请
    DRY POWDER DRUG DELIVERY SYSTEMS AND METHODS 审中-公开
    干粉药物递送系统和方法

    公开(公告)号：WO2014012069A2

    公开(公告)日：2014-01-16

    申请号：PCT/US2013050392

    申请日：2013-07-12

    申请人： MANNKIND CORP

    发明人： SMUTNEY CHAD C ,  ADAMO BENOIT ,  LAURENZI BRENDAN F ,  KINSEY P SPENCER

    IPC分类号： A61M15/00

    CPC分类号： A61M15/00 ,  A61M11/001 ,  A61M15/0005 ,  A61M15/002 ,  A61M15/0021 ,  A61M15/0025 ,  A61M15/0028 ,  A61M15/0065 ,  A61M2016/0027 ,  A61M2202/064 ,  A61M2205/076 ,  A61M2206/14 ,  A61M2206/16 ,  A61M2206/20

    摘要： A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

    摘要翻译： 公开了一种肺部药物输送系统，其包括呼吸驱动的干粉吸入器，带有或不带有用于输送干粉制剂的药筒。 吸入器和药筒可以配备包含例如二酮哌嗪和活性成分（包括小有机分子，肽和蛋白质，包括诸如胰岛素和胰高血糖素样肽1的激素）的药物递送制剂，用于治疗 疾病和病症，例如疾病和病症，包括内分泌疾病如糖尿病和/或肥胖症。